만성 건선 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.1%로 293억 3,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장은 만성 건선(CPP)의 세계 유병률 증가 또는 감소, 자가면역 질환 증가, 의료 예산 증가, 고령화, 효과적인 치료법에 대한 수요 증가 등의 요인에 기인합니다. 이 기간 중 예상되는 주요 동향으로는 생물학적 치료의 발전, 경구용 저분자 억제제의 개발, 디지털 헬스 기술의 통합, 맞춤형 의료의 부상, 바이오시밀러의 도입 등이 있습니다.
면역계 기능 장애의 유병률 증가는 만성 건선 시장의 성장을 가속할 것으로 예측됩니다. 면역계 기능 장애는 면역계가 제대로 작동하지 않아 감염, 자가면역질환, 암의 위험을 증가시키는 것으로 알려져 있습니다. 이러한 증가 요인으로는 유전적 소인, 환경적 요인, 영양 부족, 만성 스트레스, 자가면역질환 및 HIV와 같은 감염성 질환의 만연 등이 있습니다. 만성 건선 치료는 면역 체계의 기능 장애를 관리하는 것이 필수적입니다. 면역 체계가 피부 세포의 과잉 생산을 유발하여 염증과 플라크 형성을 유발할 수 있기 때문입니다. 예를 들어 2022년 12월 미국의 비영리단체인 National Psoriasis Foundation은 800만 명 이상의 미국인이 건선을 앓고 있으며, 전 세계에서는 전 세계 인구의 2-3%에 해당하는 1억 2,500만 명이 건선을 앓고 있다고 보고했습니다. 이에 따라 면역계 기능 장애 사례가 증가하고 있으며, 만성 건선 시장 확대에 박차를 가하고 있습니다.
만성 건선 시장의 주요 기업은 만성 건선 치료를 발전시키기 위해 IL-17A 및 IL-17F 억제제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 이들 억제제는 면역 반응에 관여하는 염증성 사이토카인인 인터류킨-17A와 인터류킨-17F를 억제하는 표적 생물학적 치료제로, 만성 건선과 같은 자가면역질환의 염증을 억제하는 데 도움이 됩니다. 예를 들어 2023년 10월 벨기에에 본사를 둔 바이오 제약사 UCB S.A.는 BIMZELX(bimekizumab-bkzx)가 미국 식품의약국(FDA)으로부터 전신요법 또는 광선요법의 후보인 중등도에서 중증의 심상성 건선 성인 환자들을 위한 치료제로 승인받았다고 발표했습니다. 승인했다고 발표했습니다. 비멕시주맙은 염증에 관여하는 두 가지 중요한 사이토카인인 인터류킨 17A(IL-17A)와 인터류킨 17F(IL-17F)를 표적으로 하여 이를 억제하도록 특별히 설계된 최초의 건선 치료제입니다. 이번 승인은 중등도에서 중증의 판상 건선 환자 1,480명을 대상으로 안전성과 유효성을 평가한 3건의 3상 다기관 임상 3상(BE READY, BE VIVID, BE SURE) 데이터를 바탕으로 이뤄졌습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 만성 건선 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 만성 건선 시장 : 성장률 분석
- 세계의 만성 건선 시장 실적 : 규모와 성장, 2019-2024
- 세계의 만성 건선 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 만성 건선 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 만성 건선 시장 : 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 생물제제
- 저분자 의약품
- 세계의 만성 건선 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 주사제
- 경구
- 국소
- 세계의 만성 건선 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 온라인 약국
- 소매 약국
- 세계의 만성 건선 시장, 생물제제의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 종양괴사인자(TNF) 저해제
- 인터류킨 저해제(IL-12, IL-23, IL-17, IL-22)
- T세포 저해제
- 기타
- 세계의 만성 건선 시장, 저분자 의약품의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- PDE4(Phosphodiesterase 4) 저해제
- 야누스 키나아제(JAK) 저해제
- 레티노이드
- 기타
제7장 지역별·국가별 분석
- 세계의 만성 건선 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 만성 건선 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 만성 건선 시장 : 경쟁 구도
- 만성 건선 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim
- Biogen Inc.
- UCB S.A.
- Dr. Reddy's Laboratories
- Innovent Biologics Inc.
- Dong-A ST Co. Ltd.
- Alumis GmbH Co KG
- Zai Lab Limited
- GC Cell Corporation
- Affibody AB
- Nimbus Therapeutics
- Bio-Thera Solutions
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 만성 건선 시장 2029 : 새로운 기회를 제공하는 국가
- 만성 건선 시장 2029 : 새로운 기회를 제공하는 부문
- 만성 건선 시장 2029 : 성장 전략
제36장 부록
KSA
Chronic plaque psoriasis is a long-lasting, inflammatory skin condition marked by the development of well-defined, raised, red patches covered with silvery-white scales. These plaques commonly appear on areas such as the scalp, elbows, knees, and lower back, though they can form anywhere on the body. It is an autoimmune disorder where the immune system accelerates the turnover of skin cells, causing them to accumulate on the surface.
The primary drug classes used for treating chronic plaque psoriasis include biologics and small-molecule drugs. Biologics are advanced medications derived from living organisms that specifically target components of the immune system to treat various conditions. These drugs are available in injectable, oral, and topical forms and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.
The chronic plaque psoriasis market research report is one of a series of new reports from The Business Research Company that provides chronic plaque psoriasis market statistics, including chronic plaque psoriasis industry global market size, regional shares, competitors with a chronic plaque psoriasis market share, detailed chronic plaque psoriasis market segments, market trends and opportunities, and any further data you may need to thrive in the chronic plaque psoriasis industry. This chronic plaque psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chronic plaque psoriasis market size has grown strongly in recent years. It will grow from $20.79 billion in 2024 to $22.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of psoriasis, a rise in co-morbidities, favorable reimbursement policies, higher consumption of alcohol and smoking, and the growing adoption of telemedicine.
The chronic plaque psoriasis market size is expected to see strong growth in the next few years. It will grow to $29.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth anticipated during the forecast period can be attributed to factors such as the rising or declining global prevalence of chronic plaque psoriasis (CPP), an increase in autoimmune diseases, growth in healthcare budgets, an aging population, and the growing demand for effective treatments. Key trends expected during this period include advancements in biologic treatments, the development of oral small molecule inhibitors, the integration of digital health technologies, the rise of personalized medicine, and the introduction of biosimilars.
The rising incidence of immune system dysfunction is expected to drive growth in the chronic plaque psoriasis market. Immune system dysfunction occurs when the immune system fails to function properly, resulting in a higher risk of infections, autoimmune diseases, and cancer. Contributing factors to this increase include genetic predispositions, environmental triggers, malnutrition, chronic stress, and the growing prevalence of autoimmune diseases and infections such as HIV. Chronic plaque psoriasis treatment is essential to manage immune system dysfunction, as the immune system erroneously causes an overproduction of skin cells, leading to inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, a US-based nonprofit organization, reported that more than 8 million Americans are affected by psoriasis, while globally, the condition impacts 125 million people, representing 2 to 3% of the world's population. As a result, the growing cases of immune system dysfunction are fueling the expansion of the chronic plaque psoriasis market.
Leading companies in the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to make progress in treating chronic plaque psoriasis. These inhibitors are targeted biologic therapies that block the pro-inflammatory cytokines interleukin-17A and interleukin-17F, which play a role in the immune response, helping to reduce inflammation in autoimmune conditions such as chronic plaque psoriasis. For example, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the first psoriasis treatment specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines involved in inflammation. Its approval was based on data from three Phase 3 multicenter trials-BE READY, BE VIVID, and BE SURE-which evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.
In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for an undisclosed sum. This acquisition strengthens Organon's dermatology portfolio by adding VTAMA (tapinarof) Cream, 1%, an innovative dermatologic treatment. VTAMA Cream is a novel, nonbiologic, non-steroidal topical therapy that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based company dedicated to developing and commercializing groundbreaking therapies in the field of immunodermatology.
Major players in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy's Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., and Arcutis Biotherapeutics.
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic plaque psoriasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the chronic plaque psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chronic plaque psoriasis market consists of revenues earned by entities by providing services such as medication delivery services, customized treatment plans, and genetic and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic plaque psoriasis market also includes sales of vitamin D analogues, combination topicals, phosphodiesterase-4 inhibitors, and janus kinase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chronic Plaque Psoriasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chronic plaque psoriasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chronic plaque psoriasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic plaque psoriasis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Biologics; Small Molecule Drugs
- 2) By Route Of Administration: Injectable; Oral; Topical
- 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- Subsegments:
- 1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others
- 2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Chronic Plaque Psoriasis Market Characteristics
3. Chronic Plaque Psoriasis Market Trends And Strategies
4. Chronic Plaque Psoriasis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Chronic Plaque Psoriasis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Chronic Plaque Psoriasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Chronic Plaque Psoriasis Market Growth Rate Analysis
- 5.4. Global Chronic Plaque Psoriasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Chronic Plaque Psoriasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Chronic Plaque Psoriasis Total Addressable Market (TAM)
6. Chronic Plaque Psoriasis Market Segmentation
- 6.1. Global Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Biologics
- Small Molecule Drugs
- 6.2. Global Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injectable
- Oral
- Topical
- 6.3. Global Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.4. Global Chronic Plaque Psoriasis Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tumor Necrosis Factor (TNF) Inhibitors
- Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22)
- T-Cell Inhibitors
- Others
- 6.5. Global Chronic Plaque Psoriasis Market, Sub-Segmentation Of Small Molecule Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Phosphodiesterase 4 (PDE4) Inhibitors
- Janus Kinase (JAK) Inhibitors
- Retinoids
- Others
7. Chronic Plaque Psoriasis Market Regional And Country Analysis
- 7.1. Global Chronic Plaque Psoriasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Chronic Plaque Psoriasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Chronic Plaque Psoriasis Market
- 8.1. Asia-Pacific Chronic Plaque Psoriasis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Chronic Plaque Psoriasis Market
- 9.1. China Chronic Plaque Psoriasis Market Overview
- 9.2. China Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Chronic Plaque Psoriasis Market
- 10.1. India Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Chronic Plaque Psoriasis Market
- 11.1. Japan Chronic Plaque Psoriasis Market Overview
- 11.2. Japan Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Chronic Plaque Psoriasis Market
- 12.1. Australia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Chronic Plaque Psoriasis Market
- 13.1. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Chronic Plaque Psoriasis Market
- 14.1. South Korea Chronic Plaque Psoriasis Market Overview
- 14.2. South Korea Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Chronic Plaque Psoriasis Market
- 15.1. Western Europe Chronic Plaque Psoriasis Market Overview
- 15.2. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Chronic Plaque Psoriasis Market
- 16.1. UK Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Chronic Plaque Psoriasis Market
- 17.1. Germany Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Chronic Plaque Psoriasis Market
- 18.1. France Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Chronic Plaque Psoriasis Market
- 19.1. Italy Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Chronic Plaque Psoriasis Market
- 20.1. Spain Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Chronic Plaque Psoriasis Market
- 21.1. Eastern Europe Chronic Plaque Psoriasis Market Overview
- 21.2. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Chronic Plaque Psoriasis Market
- 22.1. Russia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Chronic Plaque Psoriasis Market
- 23.1. North America Chronic Plaque Psoriasis Market Overview
- 23.2. North America Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Chronic Plaque Psoriasis Market
- 24.1. USA Chronic Plaque Psoriasis Market Overview
- 24.2. USA Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Chronic Plaque Psoriasis Market
- 25.1. Canada Chronic Plaque Psoriasis Market Overview
- 25.2. Canada Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Chronic Plaque Psoriasis Market
- 26.1. South America Chronic Plaque Psoriasis Market Overview
- 26.2. South America Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Chronic Plaque Psoriasis Market
- 27.1. Brazil Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Chronic Plaque Psoriasis Market
- 28.1. Middle East Chronic Plaque Psoriasis Market Overview
- 28.2. Middle East Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Chronic Plaque Psoriasis Market
- 29.1. Africa Chronic Plaque Psoriasis Market Overview
- 29.2. Africa Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Chronic Plaque Psoriasis Market Competitive Landscape And Company Profiles
- 30.1. Chronic Plaque Psoriasis Market Competitive Landscape
- 30.2. Chronic Plaque Psoriasis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Chronic Plaque Psoriasis Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. Eli Lilly and Company
- 31.3. Amgen Inc.
- 31.4. Boehringer Ingelheim
- 31.5. Biogen Inc.
- 31.6. UCB S.A.
- 31.7. Dr. Reddy's Laboratories
- 31.8. Innovent Biologics Inc.
- 31.9. Dong-A ST Co. Ltd.
- 31.10. Alumis GmbH Co KG
- 31.11. Zai Lab Limited
- 31.12. GC Cell Corporation
- 31.13. Affibody AB
- 31.14. Nimbus Therapeutics
- 31.15. Bio-Thera Solutions
32. Global Chronic Plaque Psoriasis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Chronic Plaque Psoriasis Market
34. Recent Developments In The Chronic Plaque Psoriasis Market
35. Chronic Plaque Psoriasis Market High Potential Countries, Segments and Strategies
- 35.1 Chronic Plaque Psoriasis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Chronic Plaque Psoriasis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Chronic Plaque Psoriasis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
